Clinical value of multiparameters of 2-[ 18 F]-fluoro-2-deoxy-glucose PET/MRI in tumor/lymph node staging of esophageal squamous cell carcinoma

2-[18F]-氟-2-脱氧葡萄糖PET/MRI多参数在食管鳞状细胞癌肿瘤/淋巴结分期中的临床价值

阅读:1

Abstract

PURPOSE: We aimed to determine the role of integrated 2-[ 18 F]-fluoro-2-deoxy-glucose ( 18 F-FDG) PET/MRI in preoperative T and N staging and prognosis of esophageal squamous cell carcinoma (ESCC). MATERIALS AND METHODS: The analysis was conducted on 66 ESCC patients who accepted 18 F-FDG-PET/MRI examinations per-operatively. We select the primary lesion as the region of interest to evaluate the diagnostic efficiency of T and N staging. Univariate and stepwise multivariate logistic regression models were performed to determine the T and N staging factors, and we established the optimal prediction model by using the Akaike information criterion. Finally, Cox regression was used for the early recurrence analyses. RESULTS: The total lesion glycolysis (TLG), metabolic tumor volume (MTV), minimum apparent diffusion coefficient (ADC min ), and mean apparent diffusion coefficient (ADC mean ) were significant in univariate analysis with T staging. None of the parameters were significant in the univariate analysis with N staging. Cox regression validated that this model-combining TLG (>47.5), MTV (>9.4 cm 3 ), ADC min (<1.49 × 10 -3 mm 2 /s), and ADC mean (<1.68 × 10 -3 mm 2 /s)-was the sole predictor significant associated with early tumor recurrence. Notably, no association was found between any single variable and early tumor recurrence. CONCLUSION: Integrated 18 F-FDG PET/MRI is feasible for preoperative T and N staging of ESCC. The optimal model is composed of TLG, MTV, ADC min, and ADC mean -all parameters derived from 18 F-FDG-PET/MRI-which not only provide valuable information for T staging but also predict early recurrence within the first postoperative year.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。